Fusion proteins are recombinant therapeutics that combine two functionally-distinct protein domains into a single molecule, typically pairing a receptor-binding or ligand-binding domain with the Fc portion of human IgG for extended half-life and stability. The Fc anchor turns short-lived signaling proteins into once-monthly or twice-monthly subcutaneous therapies, and the design approach has produced multiple approved and late-stage drugs across autoimmune, cardiovascular, and rare-disease indications.
Coverage on this site focuses on the fusion protein franchises that intersect the peptide therapeutics landscape. Vera Therapeutics's [[trutakna]] (atacicept-vymj) combines the TACI extracellular domain with human IgG1 Fc, neutralizing BAFF and APRIL; FDA accelerated approval for adult primary IgA nephropathy landed July 7, 2026. Vertex's povetacicept is an engineered dual BAFF/APRIL inhibitor fusion protein with FDA BLA acceptance and a November 30, 2026 PDUFA target action date after the Phase 3 RAINIER interim analysis documented 52% UPCR reduction at Week 36. Kiniksa Pharmaceuticals's ARCALYST (rilonacept) is an IL-1α and IL-1β cytokine-trap fusion protein for recurrent pericarditis; Q2 2026 net product revenue reached $243.6 million (+55% YoY). Lerodalcibep (Lyrokaul), an adnectin-Fc fusion protein PCSK9 inhibitor for hypercholesterolemia, received EMA CHMP recommendation for EU marketing authorisation at the July 20-23 meeting and prior US FDA approval as Lerochol.
Fusion proteins share the once-monthly or twice-monthly subcutaneous administration profile that competes with both traditional injectable antibodies (weekly or every-two-weeks) and emerging oral peptide alternatives (daily). Stories here cover trial readouts, approvals, and commercial launches across the class. See [[trutakna]], [[atacicept]], [[povetacicept]], [[rilonacept]], and [[lerodalcibep]] for adjacent threads.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2026 financial results Tuesday July 28, 2026 with ARCALYST (rilonacept, an IL-1α and IL-1β cytokine trap fusion protein) net product revenue of $243.6 million, +55% year-over-year growth. ARCALYST is FDA-approved for the reduction in risk of recurrence of pericarditis in patients 12 years of age and older, and represents Kiniksa's primary commercial franchise. The Q2 revenue trajectory reflects continued cardiovascular-specialist adoption of rilonacept as a maintenance therapy alternative to colchicine-plus-corticosteroid regimens in the recurrent pericarditis population. Kiniksa separately reported Phase 2 data from the KPL-387 program (an investigational IL-1 receptor antagonist monoclonal antibody) showing rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous injection administered once monthly. The company hosted a conference call and webcast at 8:30 AM Eastern Time Tuesday July 28 to discuss Q2 financial performance and portfolio pipeline advancement including KPL-387 next-step development, ARCALYST commercial expansion, and additional pipeline candidates. Kiniksa Pharmaceuticals is one of the peptide-adjacent biotech companies focused on IL-1 pathway inhibition through both antibody and fusion-protein modalities.
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) closed its July 20-23, 2026 meeting with a recommendation for EU marketing authorisation of Lyrokaul (lerodalcibep). Lerodalcibep is a third-generation PCSK9 inhibitor administered as a once-monthly self-administered subcutaneous injection. The active substance is an adnectin-Fc fusion protein that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9-mediated degradation of LDL receptors in the liver and enhancing LDL-C clearance from circulation. In the Phase 3 LIBerate-HeFH registrational trial, adults with heterozygous familial hypercholesterolaemia (HeFH) on maximally tolerated statin therapy achieved placebo-adjusted LDL-C reductions of roughly 59-65% by Week 24, with approximately two-thirds of participants reaching European Society of Cardiology-recommended targets. The CHMP recommendation covers use in addition to diet, alone or in combination with other lipid-lowering therapies. European Commission marketing authorisation decisions typically follow CHMP recommendations by 2-3 months. Lerodalcibep received US FDA approval earlier in 2026 under the brand name Lerochol. The EU authorization would add a third-generation PCSK9 modality alongside injectable antibodies (Repatha/evolocumab, Praluent/alirocumab), the siRNA (Leqvio/inclisiran), and the oral macrocyclic peptide (LIPFENDRA/enlicitide, US-only as of July 25, 2026).
The FDA granted accelerated approval Tuesday July 7, 2026 to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, in combination with standard of care. Vera Therapeutics developed the drug as a recombinant fusion protein that combines the extracellular domain of the transmembrane activator and CAML interactor (TACI) receptor with the Fc portion of human IgG1, binding both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) to reduce autoantibody-driven kidney damage. The registrational Phase 3 ORIGIN trial data supporting approval: at 36 weeks, Trutakna plus standard of care produced a 45.7% reduction in urine protein-to-creatinine ratio versus a 6.8% reduction for standard of care alone. IgA nephropathy affects approximately 130,000 to 150,000 Americans and is the most common primary glomerular disease worldwide; approximately 40% of patients progress to end-stage renal disease within 20 years without adequate treatment. Trutakna is a fusion protein rather than a peptide but sits in adjacent therapeutic territory relevant to the site's peptide-and-biologic coverage. Vera Therapeutics (NASDAQ: VERA) is expected to launch the product in Q3 2026. Continued approval may be contingent on verification of clinical benefit in confirmatory Phase 3 studies.